β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature
about
Protective Role for LPA3 in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol.Protection effect of survivin protein overexpression on acute myocardial infarction in rats.Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease.Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications.The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy.Pathophysiology and prevention of sudden cardiac death.Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm.Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome.Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence.Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular DysfunctionThe relationship between obesity and hypertension: an updated comprehensive overview on vicious twins.Nocturnal light pollution and underexposure to daytime sunlight: Complementary mechanisms of circadian disruption and related diseases.Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.Tert-butylhydroquinone promotes angiogenesis and improves heart functions in rats after myocardial infarction.New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging
P2860
Q33736651-1C76CAD3-B140-4ED4-94F4-C31740DF4783Q36182887-4573FAA7-967B-48DE-8EB3-589445510AB5Q37471531-DB2FEB6B-5504-4529-A675-EEC4DE0DFEDCQ38610953-9AED8437-F2FE-48FE-9D7E-CF6E53BB4313Q38622658-4CAE96AA-1D93-4B77-8996-9548C78ED3E2Q38664314-CA2ACCE1-A884-4161-8061-E1B0F254E41EQ38846534-DB1B9F3F-EB29-4EC5-A238-454240143891Q38859863-7C523B72-BC4A-4187-8AB8-A5FF0B6E2445Q38990014-4FB526B8-3E3C-4557-B950-DFA977A1CB8FQ40761254-B5523706-8F7A-4FC5-AD30-9429783C22C5Q41991038-53731BF6-287B-44F0-8000-1F692A6D88AEQ47936966-77D02B3E-81EE-4642-A961-D3936D6FBDA8Q50535266-25682E1C-BD50-4B4B-842D-C1567C3B69FFQ55000155-16A5ACD3-71A1-4564-9F09-CA41899EDF12Q58790122-10C30C40-DE0E-4768-B42B-0B5CD93AE34F
P2860
β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
β-Blockers in hypertension, di ...... on: a review of the literature
@ast
β-Blockers in hypertension, di ...... on: a review of the literature
@en
β-Blockers in hypertension, di ...... on: a review of the literature
@nl
type
label
β-Blockers in hypertension, di ...... on: a review of the literature
@ast
β-Blockers in hypertension, di ...... on: a review of the literature
@en
β-Blockers in hypertension, di ...... on: a review of the literature
@nl
prefLabel
β-Blockers in hypertension, di ...... on: a review of the literature
@ast
β-Blockers in hypertension, di ...... on: a review of the literature
@en
β-Blockers in hypertension, di ...... on: a review of the literature
@nl
P2093
P2860
P921
P3181
P1433
P1476
β-Blockers in hypertension, di ...... on: a review of the literature
@en
P2093
Asfandyar K Niazi
Carl J Lavie
David S Bell
Enrico Cerrato
Fabrizio D'Ascenzo
Hassan Fares
James H O'Keefe
Saurav Chatterjee
P2860
P304
P3181
P356
10.1136/OPENHRT-2014-000230
P407
P577
2015-01-01T00:00:00Z